Literature DB >> 1607650

Species specificity in the interaction of CD8 with the alpha 3 domain of MHC class I molecules.

M H Newberg1, J P Ridge, D R Vining, R D Salter, V H Engelhard.   

Abstract

The alpha 1 and alpha 2 domains of the class I MHC molecule constitute the putative binding site for processed peptides and the TCR, although the alpha 3 domain has been implicated as a binding site for the CD8 molecule. Species specificity in the binding of CD8 to the alpha 3 domain has been suggested as an explanation for the low xenogeneic T cell response to class I molecules, but results on this point have been conflicting and controversial. We have addressed this issue using CTL lines from HLA-A2.1 transgenic mice that specifically recognize and lyse A2.1-expressing cells infected with influenza A/PR/8 or pulsed with influenza matrix peptide M1(57-68). Species specificity was examined using transfectants that expressed hybrid molecules containing the alpha 1 and alpha 2 domains from HLA-A2.1 and the alpha 3 domain from a murine class I molecule. Lower levels of M1(57-68) peptide were required to sensitize L cell transfectants expressing a chimera that contained an H-2Dd alpha 3 domain than targets expressing the intact A2.1 molecule. However, at high doses of peptide, lysis of these two targets was similar. However, no reproducible difference in sensitization was observed using EL4 or Jurkat transfectants expressing A2.1 or A2.1 chimeric molecules that contained an H-2Kb alpha 3 domain. In all cases, however, lysis of peptide-pulsed A2.1 expressing targets was more sensitive to inhibition with anti-CD8 mAb than lysis of cells expressing these chimeric molecules. Thus, under suboptimal conditions such as low Ag density or in the presence of anti-CD8 mAb, these CTL preferentially recognize class I molecules with a murine alpha 3 domain. This suggests that there is some species specificity in the interaction of CD8 with the alpha 3 domain of the class I molecule. However, CTL recognition was inhibited by point mutations in the alpha 3 domain of HLA-A2.1 that have been shown to inhibit binding of human CD8 and recognition by human CTL, suggesting that murine CD8 interacts to some degree with human alpha 3 domains, and that similar alpha 3 domain residues may be important for murine and human CD8 binding. The relevance of these results to an understanding of low xenogeneic responses is discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1607650

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Use of transgenic HLA A*0201/Kb and HHD II mice to evaluate frequency of cytomegalovirus IE1-derived peptide usage in eliciting human CD8 cytokine response.

Authors:  Ghislaine Gallez-Hawkins; Maria C Villacres; Xiuli Li; Margaret C Sanborn; Norma A Lomeli; John A Zaia
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

2.  Immunocompetent mouse models to evaluate intrahepatic T cell responses to HCV vaccines.

Authors:  Wenbo Yu; Branka Grubor-Bauk; Ranajoy Mullick; Saumitra Das; Eric J Gowans
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  Prophylactic DNA vaccine for hepatitis C virus (HCV) infection: HCV-specific cytotoxic T lymphocyte induction and protection from HCV-recombinant vaccinia infection in an HLA-A2.1 transgenic mouse model.

Authors:  T Arichi; T Saito; M E Major; I M Belyakov; M Shirai; V H Engelhard; S M Feinstone; J A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

4.  Demonstration of direct xenorecognition of porcine cells by human cytotoxic T lymphocytes.

Authors:  A C Cunningham; T J Butler; J A Kirby
Journal:  Immunology       Date:  1994-02       Impact factor: 7.397

5.  Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions.

Authors:  P Sarobe; C D Pendleton; T Akatsuka; D Lau; V H Engelhard; S M Feinstone; J A Berzofsky
Journal:  J Clin Invest       Date:  1998-09-15       Impact factor: 14.808

6.  Use of recombinant protein to identify a motif-negative human cytotoxic T-cell epitope presented by HLA-A2 in the hepatitis C virus NS3 region.

Authors:  K Kurokohchi; T Akatsuka; C D Pendleton; A Takamizawa; M Nishioka; M Battegay; S M Feinstone; J A Berzofsky
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

7.  Characterization of MHC class-I restricted TCRalphabeta+ CD4- CD8- double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccination.

Authors:  Simon Voelkl; Tamson V Moore; Michael Rehli; Michael I Nishimura; Andreas Mackensen; Karin Fischer
Journal:  Cancer Immunol Immunother       Date:  2008-10-03       Impact factor: 6.968

8.  Separation of thymic education from antigen presenting functions of major histocompatibility complex class I molecules.

Authors:  E Simpson; P J Robinson; P Chandler; M M Millrain; H P Pircher; D Brändle; P Tomlinson; J Antoniou; A Mellor
Journal:  Immunology       Date:  1994-01       Impact factor: 7.397

9.  Effective elicitation of human effector CD8+ T Cells in HLA-B*51:01 transgenic humanized mice after infection with HIV-1.

Authors:  Yoshinori Sato; Sayaka Nagata; Masafumi Takiguchi
Journal:  PLoS One       Date:  2012-08-06       Impact factor: 3.240

10.  Identification and enhancement of HLA-A2.1-restricted CTL epitopes in a new human cancer antigen-POTE.

Authors:  Yi-Hsiang Huang; Masaki Terabe; C David Pendleton; Deborah Stewart Khursigara; Tapan K Bera; Ira Pastan; Jay A Berzofsky
Journal:  PLoS One       Date:  2013-06-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.